デフォルト表紙
市場調査レポート
商品コード
1193131

クリ・デュ・チャット症候群治療市場:治療法別(理学療法、言語療法、作業療法)、エンドユーザー別(病院と専門クリニック、その他):世界の機会分析および産業予測、2021-2031年

Cri-du-chat Syndrome Treatment Market By Treatment (Physiotherapy, Speech therapy, Occupational therapy), By End User (Hospitals and specialty clinics, Others): Global Opportunity Analysis and Industry Forecast, 2021-2031

出版日: | 発行: Allied Market Research | ページ情報: 英文 148 Pages | 納期: 2~3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.16円
クリ・デュ・チャット症候群治療市場:治療法別(理学療法、言語療法、作業療法)、エンドユーザー別(病院と専門クリニック、その他):世界の機会分析および産業予測、2021-2031年
出版日: 2022年10月01日
発行: Allied Market Research
ページ情報: 英文 148 Pages
納期: 2~3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のクリ・デュ・チャット症候群治療市場は、2021年に133万2,460米ドル、2031年には191万8,210米ドルに達し、2022年から2031年までのCAGRは3.7%で成長すると予測されます。

クリ・デュ・チャット症候群は、5p-症候群や猫鳴き症候群としても知られており、5番染色体の短腕(p腕)から遺伝物質が欠失することによってもたらされるまれな遺伝性疾患です。この異常な染色体欠損は、原因が不明です。高い声で泣き、頭が小さく、鼻梁が平らになっているのが、クリ・デュ・チャット症候群の赤ちゃんの特徴です。

約5万人に1人の割合で発症していると言われています。この推定値は減少傾向にあります。より高度で定期的な遺伝子検査が行われ、多くの軽症例が発見されるようになったため、25,000人に1人という低い割合になる可能性があります。このように、クリデュシャット症候群の高い有病率と、遺伝性疾患の診断の増加が、市場の成長を後押ししています。

この症候群は、利用可能な特定の薬理学的治療法がありません。この遺伝子疾患を持つ子どもは、その可能性を最大限に発揮するために、両親、セラピスト、医療・教育の専門家からなるチームによる継続的なケアが必要でしょう。早期から一貫した理学療法、作業療法、言語療法を行うことで、子どもたちの可能性を最大限に引き出し、充実した生活を送ることができます。また、理学療法、作業療法、言語療法に関する認知度やメリットの高まりが、市場を牽引する主な要因となっています。疾病の蔓延と自己負担の増加により、ヘルスケアコストが大幅に上昇しています。これらの要因が市場成長を促進しています。

しかし、治療費の高さが市場成長の妨げになることが予想されます。逆に、消費者ニーズを満たす新興市場の成長機会は、投資家にとって大きな投資機会となることが予想されます。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場の概要

  • 市場の定義と範囲
  • 主な調査結果
    • 主な投資ポケット
  • ポーターのファイブフォース分析
  • 主要企業のポジショニング
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
  • COVID-19 影響分析

第4章 クリ・デュ・チャット症候群治療市場:治療別

  • 概要
    • 市場規模および予測
  • 理学療法
    • 主な市場動向、成長要因、機会
    • 市場規模・予測:地域別
    • 市場シェア分析:国別
  • 音声療法
    • 主な市場動向、成長要因、機会
    • 市場規模・予測:地域別
    • 市場シェア分析:国別
  • 作業療法
    • 主な市場動向、成長要因、機会
    • 市場規模・予測:地域別
    • 市場シェア分析:国別

第5章 クリ・デュ・チャット症候群治療市場:エンドユーザー別

  • 概要
    • 市場規模・予測
  • 病院および専門クリニック
    • 主な市場動向、成長要因、機会
    • 市場規模・予測:地域別
    • 市場シェア分析:国別
  • その他
    • 主な市場動向、成長要因、機会
    • 市場規模・予測:地域別
    • 市場シェア分析:国別

第6章 クリ・デュ・チャット症候群治療薬市場:地域別

  • 概要
    • 市場規模・予測
  • 北米
    • 主な動向と機会
    • 北米市場規模・予測:治療法別
    • 北米市場規模・予測:エンドユーザー別
    • 北米市場規模・予測:国別
      • 米国
      • カナダ
      • メキシコ
  • 欧州
    • 主な動向と機会
    • 欧州の市場規模・予測:治療法別
    • 欧州市場規模・予測:エンドユーザー別
    • 欧州市場規模・予測:国別
      • ドイツ
      • フランス
      • 英国
      • イタリア
      • スペイン
      • その他の欧州地域
  • アジア太平洋地域
    • 主な動向と機会
    • アジア太平洋地域の市場規模・予測:治療法別
    • アジア太平洋地域の市場規模・予測:エンドユーザー別
    • アジア太平洋地域の市場規模・予測:国別
      • 日本
      • 中国
      • インド
      • オーストラリア
      • 韓国
      • その他アジア太平洋地域
  • LAMEA
    • 主な動向と機会
    • LAMEAの市場規模・予測:治療法別
    • LAMEAの市場規模・予測:エンドユーザー別
    • LAMEAの市場規模・予測:国別
      • ブラジル
      • サウジアラビア
      • 南アフリカ共和国
      • LAMEAの残りの地域

第7章 企業情勢

  • イントロダクション
  • 主要成功戦略
  • 主要10社の製品マッピング
  • 競合ダッシュボード
  • 競合ヒートマップ
  • 主な発展

第8章 企業プロファイル

  • Hoppers Physio
  • Jeevam Therapy
  • Physiocomestoyou
  • EURO-THERAPIES
  • Institute for Child Development
  • Blossoms Physiotherapy
  • Pediatric Advanced Therapy
  • Chatham Speech and Myo
  • Movement Masters Physical Therapy
  • Rio Children's Hospital
図表

LIST OF TABLES

  • TABLE 1. GLOBAL CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $THOUSAND)
  • TABLE 2. CRI-DU-CHAT SYNDROME TREATMENT MARKET FOR PHYSIOTHERAPY, BY REGION, 2021-2031 (REVENUE, $THOUSAND)
  • TABLE 3. CRI-DU-CHAT SYNDROME TREATMENT MARKET FOR PHYSIOTHERAPY, BY COUNTRY, 2021-2031 (REVENUE, $THOUSAND)
  • TABLE 4. CRI-DU-CHAT SYNDROME TREATMENT MARKET FOR SPEECH THERAPY, BY REGION, 2021-2031 (REVENUE, $THOUSAND)
  • TABLE 5. CRI-DU-CHAT SYNDROME TREATMENT MARKET FOR SPEECH THERAPY, BY COUNTRY, 2021-2031 (REVENUE, $THOUSAND)
  • TABLE 6. CRI-DU-CHAT SYNDROME TREATMENT MARKET FOR OCCUPATIONAL THERAPY, BY REGION, 2021-2031 (REVENUE, $THOUSAND)
  • TABLE 7. CRI-DU-CHAT SYNDROME TREATMENT MARKET FOR OCCUPATIONAL THERAPY, BY COUNTRY, 2021-2031 (REVENUE, $THOUSAND)
  • TABLE 8. GLOBAL CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY END USER, 2021-2031 (REVENUE, $THOUSAND)
  • TABLE 9. CRI-DU-CHAT SYNDROME TREATMENT MARKET FOR HOSPITALS AND SPECIALTY CLINICS, BY REGION, 2021-2031 (REVENUE, $THOUSAND)
  • TABLE 10. CRI-DU-CHAT SYNDROME TREATMENT MARKET FOR HOSPITALS AND SPECIALTY CLINICS, BY COUNTRY, 2021-2031 (REVENUE, $THOUSAND)
  • TABLE 11. CRI-DU-CHAT SYNDROME TREATMENT MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $THOUSAND)
  • TABLE 12. CRI-DU-CHAT SYNDROME TREATMENT MARKET FOR OTHERS, BY COUNTRY, 2021-2031 (REVENUE, $THOUSAND)
  • TABLE 13. CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY REGION, 2021-2031 (REVENUE, $THOUSAND)
  • TABLE 14. NORTH AMERICA CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $THOUSAND)
  • TABLE 15. NORTH AMERICA CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY END USER, 2021-2031 (REVENUE, $THOUSAND)
  • TABLE 16. NORTH AMERICA CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY COUNTRY, 2021-2031 (REVENUE, $THOUSAND)
  • TABLE 17. U.S. CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $THOUSAND)
  • TABLE 18. U.S. CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY END USER, 2021-2031 (REVENUE, $THOUSAND)
  • TABLE 19. CANADA CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $THOUSAND)
  • TABLE 20. CANADA CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY END USER, 2021-2031 (REVENUE, $THOUSAND)
  • TABLE 21. MEXICO CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $THOUSAND)
  • TABLE 22. MEXICO CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY END USER, 2021-2031 (REVENUE, $THOUSAND)
  • TABLE 23. EUROPE CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $THOUSAND)
  • TABLE 24. EUROPE CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY END USER, 2021-2031 (REVENUE, $THOUSAND)
  • TABLE 25. EUROPE CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY COUNTRY, 2021-2031 (REVENUE, $THOUSAND)
  • TABLE 26. GERMANY CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $THOUSAND)
  • TABLE 27. GERMANY CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY END USER, 2021-2031 (REVENUE, $THOUSAND)
  • TABLE 28. FRANCE CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $THOUSAND)
  • TABLE 29. FRANCE CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY END USER, 2021-2031 (REVENUE, $THOUSAND)
  • TABLE 30. UK CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $THOUSAND)
  • TABLE 31. UK CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY END USER, 2021-2031 (REVENUE, $THOUSAND)
  • TABLE 32. ITALY CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $THOUSAND)
  • TABLE 33. ITALY CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY END USER, 2021-2031 (REVENUE, $THOUSAND)
  • TABLE 34. SPAIN CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $THOUSAND)
  • TABLE 35. SPAIN CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY END USER, 2021-2031 (REVENUE, $THOUSAND)
  • TABLE 36. REST OF EUROPE CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $THOUSAND)
  • TABLE 37. REST OF EUROPE CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY END USER, 2021-2031 (REVENUE, $THOUSAND)
  • TABLE 38. ASIA-PACIFIC CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $THOUSAND)
  • TABLE 39. ASIA-PACIFIC CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY END USER, 2021-2031 (REVENUE, $THOUSAND)
  • TABLE 40. ASIA-PACIFIC CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY COUNTRY, 2021-2031 (REVENUE, $THOUSAND)
  • TABLE 41. JAPAN CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $THOUSAND)
  • TABLE 42. JAPAN CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY END USER, 2021-2031 (REVENUE, $THOUSAND)
  • TABLE 43. CHINA CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $THOUSAND)
  • TABLE 44. CHINA CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY END USER, 2021-2031 (REVENUE, $THOUSAND)
  • TABLE 45. INDIA CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $THOUSAND)
  • TABLE 46. INDIA CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY END USER, 2021-2031 (REVENUE, $THOUSAND)
  • TABLE 47. AUSTRALIA CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $THOUSAND)
  • TABLE 48. AUSTRALIA CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY END USER, 2021-2031 (REVENUE, $THOUSAND)
  • TABLE 49. SOUTH KOREA CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $THOUSAND)
  • TABLE 50. SOUTH KOREA CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY END USER, 2021-2031 (REVENUE, $THOUSAND)
  • TABLE 51. REST OF ASIA-PACIFIC CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $THOUSAND)
  • TABLE 52. REST OF ASIA-PACIFIC CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY END USER, 2021-2031 (REVENUE, $THOUSAND)
  • TABLE 53. LAMEA CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $THOUSAND)
  • TABLE 54. LAMEA CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY END USER, 2021-2031 (REVENUE, $THOUSAND)
  • TABLE 55. LAMEA CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY COUNTRY, 2021-2031 (REVENUE, $THOUSAND)
  • TABLE 56. BRAZIL CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $THOUSAND)
  • TABLE 57. BRAZIL CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY END USER, 2021-2031 (REVENUE, $THOUSAND)
  • TABLE 58. SAUDI ARABIA CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $THOUSAND)
  • TABLE 59. SAUDI ARABIA CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY END USER, 2021-2031 (REVENUE, $THOUSAND)
  • TABLE 60. SOUTH AFRICA CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $THOUSAND)
  • TABLE 61. SOUTH AFRICA CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY END USER, 2021-2031 (REVENUE, $THOUSAND)
  • TABLE 62. REST OF LAMEA CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $THOUSAND)
  • TABLE 63. REST OF LAMEA CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY END USER, 2021-2031 (REVENUE, $THOUSAND)
  • TABLE 64.HOPPERS PHYSIO: COMPANY SNAPSHOT
  • TABLE 65.HOPPERS PHYSIO: OPERATING SEGMENTS
  • TABLE 66.HOPPERS PHYSIO: PRODUCT PORTFOLIO
  • TABLE 67.HOPPERS PHYSIO: NET SALES
  • TABLE 68.HOPPERS PHYSIO: KEY STRATERGIES
  • TABLE 69.JEEVAM THERAPY: COMPANY SNAPSHOT
  • TABLE 70.JEEVAM THERAPY: OPERATING SEGMENTS
  • TABLE 71.JEEVAM THERAPY: PRODUCT PORTFOLIO
  • TABLE 72.JEEVAM THERAPY: NET SALES
  • TABLE 73.JEEVAM THERAPY: KEY STRATERGIES
  • TABLE 74.PHYSIOCOMESTOYOU: COMPANY SNAPSHOT
  • TABLE 75.PHYSIOCOMESTOYOU: OPERATING SEGMENTS
  • TABLE 76.PHYSIOCOMESTOYOU: PRODUCT PORTFOLIO
  • TABLE 77.PHYSIOCOMESTOYOU: NET SALES
  • TABLE 78.PHYSIOCOMESTOYOU: KEY STRATERGIES
  • TABLE 79.EURO-THERAPIES: COMPANY SNAPSHOT
  • TABLE 80.EURO-THERAPIES: OPERATING SEGMENTS
  • TABLE 81.EURO-THERAPIES: PRODUCT PORTFOLIO
  • TABLE 82.EURO-THERAPIES: NET SALES
  • TABLE 83.EURO-THERAPIES: KEY STRATERGIES
  • TABLE 84.INSTITUTE FOR CHILD DEVELOPMENT: COMPANY SNAPSHOT
  • TABLE 85.INSTITUTE FOR CHILD DEVELOPMENT: OPERATING SEGMENTS
  • TABLE 86.INSTITUTE FOR CHILD DEVELOPMENT: PRODUCT PORTFOLIO
  • TABLE 87.INSTITUTE FOR CHILD DEVELOPMENT: NET SALES
  • TABLE 88.INSTITUTE FOR CHILD DEVELOPMENT: KEY STRATERGIES
  • TABLE 89.BLOSSOMS PHYSIOTHERAPY: COMPANY SNAPSHOT
  • TABLE 90.BLOSSOMS PHYSIOTHERAPY: OPERATING SEGMENTS
  • TABLE 91.BLOSSOMS PHYSIOTHERAPY: PRODUCT PORTFOLIO
  • TABLE 92.BLOSSOMS PHYSIOTHERAPY: NET SALES
  • TABLE 93.BLOSSOMS PHYSIOTHERAPY: KEY STRATERGIES
  • TABLE 94.PEDIATRIC ADVANCED THERAPY: COMPANY SNAPSHOT
  • TABLE 95.PEDIATRIC ADVANCED THERAPY: OPERATING SEGMENTS
  • TABLE 96.PEDIATRIC ADVANCED THERAPY: PRODUCT PORTFOLIO
  • TABLE 97.PEDIATRIC ADVANCED THERAPY: NET SALES
  • TABLE 98.PEDIATRIC ADVANCED THERAPY: KEY STRATERGIES
  • TABLE 99.CHATHAM SPEECH AND MYO: COMPANY SNAPSHOT
  • TABLE 100.CHATHAM SPEECH AND MYO: OPERATING SEGMENTS
  • TABLE 101.CHATHAM SPEECH AND MYO: PRODUCT PORTFOLIO
  • TABLE 102.CHATHAM SPEECH AND MYO: NET SALES
  • TABLE 103.CHATHAM SPEECH AND MYO: KEY STRATERGIES
  • TABLE 104.MOVEMENT MASTERS PHYSICAL THERAPY: COMPANY SNAPSHOT
  • TABLE 105.MOVEMENT MASTERS PHYSICAL THERAPY: OPERATING SEGMENTS
  • TABLE 106.MOVEMENT MASTERS PHYSICAL THERAPY: PRODUCT PORTFOLIO
  • TABLE 107.MOVEMENT MASTERS PHYSICAL THERAPY: NET SALES
  • TABLE 108.MOVEMENT MASTERS PHYSICAL THERAPY: KEY STRATERGIES
  • TABLE 109.RIO CHILDREN'S HOSPITAL: COMPANY SNAPSHOT
  • TABLE 110.RIO CHILDREN'S HOSPITAL: OPERATING SEGMENTS
  • TABLE 111.RIO CHILDREN'S HOSPITAL: PRODUCT PORTFOLIO
  • TABLE 112.RIO CHILDREN'S HOSPITAL: NET SALES
  • TABLE 113.RIO CHILDREN'S HOSPITAL: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 1.CRI-DU-CHAT SYNDROME TREATMENT MARKET SEGMENTATION
  • FIGURE 2.CRI-DU-CHAT SYNDROME TREATMENT MARKET,2021-2031
  • FIGURE 3.CRI-DU-CHAT SYNDROME TREATMENT MARKET,2021-2031
  • FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
  • FIGURE 5.PORTER FIVE-1
  • FIGURE 6.PORTER FIVE-2
  • FIGURE 7.PORTER FIVE-3
  • FIGURE 8.PORTER FIVE-4
  • FIGURE 9.PORTER FIVE-5
  • FIGURE 10.TOP PLAYER POSITIONING
  • FIGURE 11.CRI-DU-CHAT SYNDROME TREATMENT MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 12.CRI-DU-CHAT SYNDROME TREATMENT MARKET,BY TREATMENT,2021(%)
  • FIGURE 13.COMPARATIVE SHARE ANALYSIS OF PHYSIOTHERAPY CRI-DU-CHAT SYNDROME TREATMENT MARKET,2021-2031(%)
  • FIGURE 14.COMPARATIVE SHARE ANALYSIS OF SPEECH THERAPY CRI-DU-CHAT SYNDROME TREATMENT MARKET,2021-2031(%)
  • FIGURE 15.COMPARATIVE SHARE ANALYSIS OF OCCUPATIONAL THERAPY CRI-DU-CHAT SYNDROME TREATMENT MARKET,2021-2031(%)
  • FIGURE 16.CRI-DU-CHAT SYNDROME TREATMENT MARKET,BY END USER,2021(%)
  • FIGURE 17.COMPARATIVE SHARE ANALYSIS OF HOSPITALS AND SPECIALTY CLINICS CRI-DU-CHAT SYNDROME TREATMENT MARKET,2021-2031(%)
  • FIGURE 18.COMPARATIVE SHARE ANALYSIS OF OTHERS CRI-DU-CHAT SYNDROME TREATMENT MARKET,2021-2031(%)
  • FIGURE 19.CRI-DU-CHAT SYNDROME TREATMENT MARKET BY REGION,2021
  • FIGURE 20.U.S. CRI-DU-CHAT SYNDROME TREATMENT MARKET,2021-2031($THOUSAND)
  • FIGURE 21.CANADA CRI-DU-CHAT SYNDROME TREATMENT MARKET,2021-2031($THOUSAND)
  • FIGURE 22.MEXICO CRI-DU-CHAT SYNDROME TREATMENT MARKET,2021-2031($THOUSAND)
  • FIGURE 23.GERMANY CRI-DU-CHAT SYNDROME TREATMENT MARKET,2021-2031($THOUSAND)
  • FIGURE 24.FRANCE CRI-DU-CHAT SYNDROME TREATMENT MARKET,2021-2031($THOUSAND)
  • FIGURE 25.UK CRI-DU-CHAT SYNDROME TREATMENT MARKET,2021-2031($THOUSAND)
  • FIGURE 26.ITALY CRI-DU-CHAT SYNDROME TREATMENT MARKET,2021-2031($THOUSAND)
  • FIGURE 27.SPAIN CRI-DU-CHAT SYNDROME TREATMENT MARKET,2021-2031($THOUSAND)
  • FIGURE 28.REST OF EUROPE CRI-DU-CHAT SYNDROME TREATMENT MARKET,2021-2031($THOUSAND)
  • FIGURE 29.JAPAN CRI-DU-CHAT SYNDROME TREATMENT MARKET,2021-2031($THOUSAND)
  • FIGURE 30.CHINA CRI-DU-CHAT SYNDROME TREATMENT MARKET,2021-2031($THOUSAND)
  • FIGURE 31.INDIA CRI-DU-CHAT SYNDROME TREATMENT MARKET,2021-2031($THOUSAND)
  • FIGURE 32.AUSTRALIA CRI-DU-CHAT SYNDROME TREATMENT MARKET,2021-2031($THOUSAND)
  • FIGURE 33.SOUTH KOREA CRI-DU-CHAT SYNDROME TREATMENT MARKET,2021-2031($THOUSAND)
  • FIGURE 34.REST OF ASIA-PACIFIC CRI-DU-CHAT SYNDROME TREATMENT MARKET,2021-2031($THOUSAND)
  • FIGURE 35.BRAZIL CRI-DU-CHAT SYNDROME TREATMENT MARKET,2021-2031($THOUSAND)
  • FIGURE 36.SAUDI ARABIA CRI-DU-CHAT SYNDROME TREATMENT MARKET,2021-2031($THOUSAND)
  • FIGURE 37.SOUTH AFRICA CRI-DU-CHAT SYNDROME TREATMENT MARKET,2021-2031($THOUSAND)
  • FIGURE 38.REST OF LAMEA CRI-DU-CHAT SYNDROME TREATMENT MARKET,2021-2031($THOUSAND)
  • FIGURE 39. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 40. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 41. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 42.PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 43.COMPETITIVE DASHBOARD
  • FIGURE 44.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
  • FIGURE 45.HOPPERS PHYSIO.: NET SALES ($THOUSAND)
  • FIGURE 46.JEEVAM THERAPY.: NET SALES ($THOUSAND)
  • FIGURE 47.PHYSIOCOMESTOYOU.: NET SALES ($THOUSAND)
  • FIGURE 48.EURO-THERAPIES.: NET SALES ($THOUSAND)
  • FIGURE 49.INSTITUTE FOR CHILD DEVELOPMENT.: NET SALES ($THOUSAND)
  • FIGURE 50.BLOSSOMS PHYSIOTHERAPY.: NET SALES ($THOUSAND)
  • FIGURE 51.PEDIATRIC ADVANCED THERAPY.: NET SALES ($THOUSAND)
  • FIGURE 52.CHATHAM SPEECH AND MYO.: NET SALES ($THOUSAND)
  • FIGURE 53.MOVEMENT MASTERS PHYSICAL THERAPY.: NET SALES ($THOUSAND)
  • FIGURE 54.RIO CHILDREN'S HOSPITAL.: NET SALES ($THOUSAND)
目次
Product Code: A15445

The global cri-du-chat syndrome treatment market was valued at $1,332.46 thousand in 2021, and is estimated to reach $1,918.21 thousand by 2031, growing at a CAGR of 3.7% from 2022 to 2031.

Cri du chat syndrome, also known as 5p- syndrome and cat cry syndrome, is a rare genetic disorder brought on by the deletion of genetic material from the short arm of chromosome 5 (the p arm), which is responsible for the illness. This unusual chromosomal loss has an unidentified cause. A high-pitched cry, a small head, and a flattened nasal bridge are the hallmarks of a baby with cri du chat syndrome.

It is estimated that one in every 50,000 or so infants has this disease. This estimate is decreasing. It may be as low as one in 25,000 with more sophisticated and regular genetic testing and many milder cases being detected. Thus, high prevalence of cri-du-chat syndrome along with increase in diagnosis for genetic diseases drives the market growth.

This syndrome has no particular pharmacological treatments available. To assist the child reach their full potential, children born with this genetic disorder will probably need ongoing care from a team made up of the parents, therapists, and medical and educational experts. They can achieve their full potential and lead fulfilling lives with early and consistent physical therapy, occupational and speech therapy. In addition, rise in awareness and advantages about physiotherapy, occupational & speech therapy is the major factor driving the market. The increase in prevalence of disease and out-of-pocket expenditure has led to a significant rise in healthcare cost. These factors propel the market growth.

However, high cost associated with therapy treatments are expected to hinder the growth of the market. Conversely, growth opportunities in emerging market to suffice the consumer demands is expected to provide a great opportunity for the investors to invest in the market.

The cri-du-chat syndrome treatment market is segmented on the basis of treatment, end user, and region. On the basis of product, the market is categorized into physiotherapy, speech therapy and occupation therapy. On the basis of end user, it is segmented into hospitals & specialty clinics and others. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and Latin America, the Middle East, and Africa (LAMEA).

The major players profiled in the report are Hoppers Physio, Jeevam Therapy, Physiocomestoyou, EURO-THERAPIES, Institute for Child Development, Blossoms Physiotherapy, Pediatric Advanced Therapy, Chatham Speech and Myo, Movement Masters Physical Therapy, and Rio Children's Hospital.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the cri-du-chat syndrome treatment market analysis from 2021 to 2031 to identify the prevailing cri-du-chat syndrome treatment market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the cri-du-chat syndrome treatment market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global cri-du-chat syndrome treatment market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Treatment

  • Physiotherapy
  • Speech therapy
  • Occupational therapy

By End User

  • Hospitals and specialty clinics
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
  • Key Market Players
    • Hoppers Physio
    • Chatham Speech and Myo
    • Movement Masters Physical Therapy
    • Rio Children's Hospital
    • Blossoms Physiotherapy
    • Institute for Child Development
    • Pediatric Advanced Therapy
    • EURO-THERAPIES
    • Physiocomestoyou
    • Jeevam Therapy

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key market segments
  • 1.3.Key benefits to the stakeholders
  • 1.4.Research Methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Porter's five forces analysis
  • 3.4.Top player positioning
  • 3.5.Market dynamics
    • 3.5.1.Drivers
    • 3.5.2.Restraints
    • 3.5.3.Opportunities
  • 3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY TREATMENT

  • 4.1 Overview
    • 4.1.1 Market size and forecast
  • 4.2 Physiotherapy
    • 4.2.1 Key market trends, growth factors and opportunities
    • 4.2.2 Market size and forecast, by region
    • 4.2.3 Market share analysis by country
  • 4.3 Speech therapy
    • 4.3.1 Key market trends, growth factors and opportunities
    • 4.3.2 Market size and forecast, by region
    • 4.3.3 Market share analysis by country
  • 4.4 Occupational therapy
    • 4.4.1 Key market trends, growth factors and opportunities
    • 4.4.2 Market size and forecast, by region
    • 4.4.3 Market share analysis by country

CHAPTER 5: CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY END USER

  • 5.1 Overview
    • 5.1.1 Market size and forecast
  • 5.2 Hospitals and specialty clinics
    • 5.2.1 Key market trends, growth factors and opportunities
    • 5.2.2 Market size and forecast, by region
    • 5.2.3 Market share analysis by country
  • 5.3 Others
    • 5.3.1 Key market trends, growth factors and opportunities
    • 5.3.2 Market size and forecast, by region
    • 5.3.3 Market share analysis by country

CHAPTER 6: CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY REGION

  • 6.1 Overview
    • 6.1.1 Market size and forecast
  • 6.2 North America
    • 6.2.1 Key trends and opportunities
    • 6.2.2 North America Market size and forecast, by Treatment
    • 6.2.3 North America Market size and forecast, by End User
    • 6.2.4 North America Market size and forecast, by country
      • 6.2.4.1 U.S.
      • 6.2.4.1.1 Key market trends, growth factors and opportunities
      • 6.2.4.1.2 Market size and forecast, by Treatment
      • 6.2.4.1.3 Market size and forecast, by End User
      • 6.2.4.2 Canada
      • 6.2.4.2.1 Key market trends, growth factors and opportunities
      • 6.2.4.2.2 Market size and forecast, by Treatment
      • 6.2.4.2.3 Market size and forecast, by End User
      • 6.2.4.3 Mexico
      • 6.2.4.3.1 Key market trends, growth factors and opportunities
      • 6.2.4.3.2 Market size and forecast, by Treatment
      • 6.2.4.3.3 Market size and forecast, by End User
  • 6.3 Europe
    • 6.3.1 Key trends and opportunities
    • 6.3.2 Europe Market size and forecast, by Treatment
    • 6.3.3 Europe Market size and forecast, by End User
    • 6.3.4 Europe Market size and forecast, by country
      • 6.3.4.1 Germany
      • 6.3.4.1.1 Key market trends, growth factors and opportunities
      • 6.3.4.1.2 Market size and forecast, by Treatment
      • 6.3.4.1.3 Market size and forecast, by End User
      • 6.3.4.2 France
      • 6.3.4.2.1 Key market trends, growth factors and opportunities
      • 6.3.4.2.2 Market size and forecast, by Treatment
      • 6.3.4.2.3 Market size and forecast, by End User
      • 6.3.4.3 UK
      • 6.3.4.3.1 Key market trends, growth factors and opportunities
      • 6.3.4.3.2 Market size and forecast, by Treatment
      • 6.3.4.3.3 Market size and forecast, by End User
      • 6.3.4.4 Italy
      • 6.3.4.4.1 Key market trends, growth factors and opportunities
      • 6.3.4.4.2 Market size and forecast, by Treatment
      • 6.3.4.4.3 Market size and forecast, by End User
      • 6.3.4.5 Spain
      • 6.3.4.5.1 Key market trends, growth factors and opportunities
      • 6.3.4.5.2 Market size and forecast, by Treatment
      • 6.3.4.5.3 Market size and forecast, by End User
      • 6.3.4.6 Rest of Europe
      • 6.3.4.6.1 Key market trends, growth factors and opportunities
      • 6.3.4.6.2 Market size and forecast, by Treatment
      • 6.3.4.6.3 Market size and forecast, by End User
  • 6.4 Asia-Pacific
    • 6.4.1 Key trends and opportunities
    • 6.4.2 Asia-Pacific Market size and forecast, by Treatment
    • 6.4.3 Asia-Pacific Market size and forecast, by End User
    • 6.4.4 Asia-Pacific Market size and forecast, by country
      • 6.4.4.1 Japan
      • 6.4.4.1.1 Key market trends, growth factors and opportunities
      • 6.4.4.1.2 Market size and forecast, by Treatment
      • 6.4.4.1.3 Market size and forecast, by End User
      • 6.4.4.2 China
      • 6.4.4.2.1 Key market trends, growth factors and opportunities
      • 6.4.4.2.2 Market size and forecast, by Treatment
      • 6.4.4.2.3 Market size and forecast, by End User
      • 6.4.4.3 India
      • 6.4.4.3.1 Key market trends, growth factors and opportunities
      • 6.4.4.3.2 Market size and forecast, by Treatment
      • 6.4.4.3.3 Market size and forecast, by End User
      • 6.4.4.4 Australia
      • 6.4.4.4.1 Key market trends, growth factors and opportunities
      • 6.4.4.4.2 Market size and forecast, by Treatment
      • 6.4.4.4.3 Market size and forecast, by End User
      • 6.4.4.5 South Korea
      • 6.4.4.5.1 Key market trends, growth factors and opportunities
      • 6.4.4.5.2 Market size and forecast, by Treatment
      • 6.4.4.5.3 Market size and forecast, by End User
      • 6.4.4.6 Rest of Asia-Pacific
      • 6.4.4.6.1 Key market trends, growth factors and opportunities
      • 6.4.4.6.2 Market size and forecast, by Treatment
      • 6.4.4.6.3 Market size and forecast, by End User
  • 6.5 LAMEA
    • 6.5.1 Key trends and opportunities
    • 6.5.2 LAMEA Market size and forecast, by Treatment
    • 6.5.3 LAMEA Market size and forecast, by End User
    • 6.5.4 LAMEA Market size and forecast, by country
      • 6.5.4.1 Brazil
      • 6.5.4.1.1 Key market trends, growth factors and opportunities
      • 6.5.4.1.2 Market size and forecast, by Treatment
      • 6.5.4.1.3 Market size and forecast, by End User
      • 6.5.4.2 Saudi Arabia
      • 6.5.4.2.1 Key market trends, growth factors and opportunities
      • 6.5.4.2.2 Market size and forecast, by Treatment
      • 6.5.4.2.3 Market size and forecast, by End User
      • 6.5.4.3 South Africa
      • 6.5.4.3.1 Key market trends, growth factors and opportunities
      • 6.5.4.3.2 Market size and forecast, by Treatment
      • 6.5.4.3.3 Market size and forecast, by End User
      • 6.5.4.4 Rest of LAMEA
      • 6.5.4.4.1 Key market trends, growth factors and opportunities
      • 6.5.4.4.2 Market size and forecast, by Treatment
      • 6.5.4.4.3 Market size and forecast, by End User

CHAPTER 7: COMPANY LANDSCAPE

  • 7.1. Introduction
  • 7.2. Top winning strategies
  • 7.3. Product Mapping of Top 10 Player
  • 7.4. Competitive Dashboard
  • 7.5. Competitive Heatmap
  • 7.6. Key developments

CHAPTER 8: COMPANY PROFILES

  • 8.1 Hoppers Physio
    • 8.1.1 Company overview
    • 8.1.2 Company snapshot
    • 8.1.3 Operating business segments
    • 8.1.4 Product portfolio
    • 8.1.5 Business performance
    • 8.1.6 Key strategic moves and developments
  • 8.2 Jeevam Therapy
    • 8.2.1 Company overview
    • 8.2.2 Company snapshot
    • 8.2.3 Operating business segments
    • 8.2.4 Product portfolio
    • 8.2.5 Business performance
    • 8.2.6 Key strategic moves and developments
  • 8.3 Physiocomestoyou
    • 8.3.1 Company overview
    • 8.3.2 Company snapshot
    • 8.3.3 Operating business segments
    • 8.3.4 Product portfolio
    • 8.3.5 Business performance
    • 8.3.6 Key strategic moves and developments
  • 8.4 EURO-THERAPIES
    • 8.4.1 Company overview
    • 8.4.2 Company snapshot
    • 8.4.3 Operating business segments
    • 8.4.4 Product portfolio
    • 8.4.5 Business performance
    • 8.4.6 Key strategic moves and developments
  • 8.5 Institute for Child Development
    • 8.5.1 Company overview
    • 8.5.2 Company snapshot
    • 8.5.3 Operating business segments
    • 8.5.4 Product portfolio
    • 8.5.5 Business performance
    • 8.5.6 Key strategic moves and developments
  • 8.6 Blossoms Physiotherapy
    • 8.6.1 Company overview
    • 8.6.2 Company snapshot
    • 8.6.3 Operating business segments
    • 8.6.4 Product portfolio
    • 8.6.5 Business performance
    • 8.6.6 Key strategic moves and developments
  • 8.7 Pediatric Advanced Therapy
    • 8.7.1 Company overview
    • 8.7.2 Company snapshot
    • 8.7.3 Operating business segments
    • 8.7.4 Product portfolio
    • 8.7.5 Business performance
    • 8.7.6 Key strategic moves and developments
  • 8.8 Chatham Speech and Myo
    • 8.8.1 Company overview
    • 8.8.2 Company snapshot
    • 8.8.3 Operating business segments
    • 8.8.4 Product portfolio
    • 8.8.5 Business performance
    • 8.8.6 Key strategic moves and developments
  • 8.9 Movement Masters Physical Therapy
    • 8.9.1 Company overview
    • 8.9.2 Company snapshot
    • 8.9.3 Operating business segments
    • 8.9.4 Product portfolio
    • 8.9.5 Business performance
    • 8.9.6 Key strategic moves and developments
  • 8.10 Rio Children's Hospital
    • 8.10.1 Company overview
    • 8.10.2 Company snapshot
    • 8.10.3 Operating business segments
    • 8.10.4 Product portfolio
    • 8.10.5 Business performance
    • 8.10.6 Key strategic moves and developments